Rob NadlerExecutive Director, Advisory
Dr. Nadler is an Executive Director in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare sector.
Dr. Nadler has more than 13 years of investment banking and healthcare experience assisting companies on a wide range of strategic matters. During his tenure at Perella Weinberg Partners, he has advised Stada on its take private by Bain Capital and Cinven and is currently advising a number of companies in the biopharma and medtech space.
Prior to joining Perella Weinberg Partners in September of 2016, Dr. Nadler was at Nomura, where he most recently served as a Vice President responsible for Pharma and Medtech coverage. Dr. Nadler began his career as an Analyst at Lehman Brothers.
At Lehman Brothers and Nomura he actively worked with clients, advising Grifols on its acquisition of Talecris; Permira on the deal contingent hedge of its exit from Creganna; the UK Government on the sale of PRUK to Bain Capital; and GSK on its minority stake/distribution agreement with JCR Pharma and on the hedging of its Quest Diagnostics stake.
Dr. Nadler earned a science and medical degree from Imperial College.